- Conditions
- CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia, Hematological Malignancies, Non-Hodgkin's Lymphoma
- Interventions
- rituximab, ABT-263
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2025
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Stanford, California • Cleveland, Ohio + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 16,003
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Nicotine Dependence, Tobacco Smoking
- Interventions
- Oxytocin, Placebo
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Abdominal Obesity, Growth Hormone Deficiency
- Interventions
- Growth hormone releasing hormone (GHRH) 1-44, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Anti-Hepatitis A Antibody Levels in Heathy Subjects
- Interventions
- Immune Globulin (Human)
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Advanced Cancers
- Interventions
- Placebo, Glutamine, Questionnaires
- Other · Drug · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 17 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Urticaria, Idiopathic
- Interventions
- Omalizumab
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Durvalumab, Carboplatin, Abequolixron, Abraxane, Pemetrexed
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Hypothyroidism; Surgery, Head and Neck Cancer, Wound Heal, Laryngeal Cancer, Laryngeal Fistula
- Interventions
- Levothyroxine
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma
- Interventions
- Pixatimod, Nivolumab, Cyclophosphamide (low dose)
- Drug
- Lead sponsor
- Diwakar Davar
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- pemetrexed disodium
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 35
- States / cities
- Hinsdale, Illinois • Urbana, Illinois • Boston, Massachusetts + 26 more
- Conditions
- Hodgkin Lymphoma
- Interventions
- bendamustine, Etoposide, Doxorubicin, Bleomycin, Vincristine, Vinblastine, Prednisone, Filgrastim, Brentuximab Vedotin, Cyclophosphamide, DTIC, Quality of Life Measurements, Radiotherapy
- Drug · Other · Radiation
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 8
- States / cities
- Palo Alto, California • Peoria, Illinois • Baton Rouge, Louisiana + 4 more
- Conditions
- Shoulder Arthroscopy, Knee Arthroscopy
- Interventions
- Sugar pill, Gabapentin, Clonidine
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neoplasms, Ovarian
- Interventions
- SB-485232 (interleukin 18), pegylated liposomal doxorubicin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 3
- States / cities
- Stanford, California • Miami, Florida • Philadelphia, Pennsylvania
- Conditions
- Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
- Interventions
- Sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide), Insulin (glargine)
- Drug
- Lead sponsor
- GRADE Study Group
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 7,850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 28 more
- Conditions
- Breast Cancer
- Interventions
- Doxorubicin, Cyclophosphamide, Paclitaxel, Carboplatin, GM-CSF, Trastuzumab
- Drug
- Lead sponsor
- Rita Sanghvi, Mehta
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- QGE031, Omalizumab, Placebo
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 22 more
- Conditions
- Gastrointestinal Symptoms
- Interventions
- Prog: Purify-2
- Other
- Lead sponsor
- Nature's Sunshine Products, Inc.
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Lehi, Utah
- Conditions
- Obesity and Overweight, HIV, Chronic Inflammation
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- University of Hawaii
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Candidemia, Candidiasis, Invasive
- Interventions
- Fosmanogepix, Caspofungin, Fluconazole, Placebo
- Drug
- Lead sponsor
- Basilea Pharmaceutica
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 17 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Betaferon/Betaseron
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 51
- States / cities
- Tucson, Arizona • Berkeley, California • Irvine, California + 46 more
- Conditions
- Hip Dysplasia
- Interventions
- Ropivacaine, Epinephrine, Ketorolac, NaCl (Saline)
- Combination Product
- Lead sponsor
- Michael C Willey
- Other
- Eligibility
- 13 Years to 50 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Sickle Cell Anemia, Severe Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH), Pure Red Cell Aplasia
- Interventions
- Campath, Chemo and/or TBI Allo SCT
- Drug
- Lead sponsor
- David Rizzieri, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2009
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Durham, North Carolina
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- filgrastim, carboplatin, cyclophosphamide, etoposide, thiotepa, autologous bone marrow transplantation, bone marrow ablation with stem cell support, conventional surgery, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Norfolk, Virginia
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- LN-145, Durvalumab
- Biological · Drug
- Lead sponsor
- Iovance Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 8
- States / cities
- La Jolla, California • Los Angeles, California • Louisville, Kentucky + 5 more